| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
Purity: =98.03%
| Targets |
Natural lignans; HSV-1/herpes simplex virus type 1
|
|---|---|
| ln Vitro |
In human lung adenocarcinoma A549 and CL1-5 cells, yatein promotes cell cycle arrest in the G2/M phase (5 μM; 24 hours) and increases G2/M phase-related protein expression (5 μM; 6–12 hours) [3]. In human A549 and CL1-5 cells, atein (5 μM; 6–12 hours) causes DNA damage by triggering the ATM/ATR pathway [3]. Yatein (5 μM; 6 h) inhibits tubulin polymerization, which changes microtubule dynamics [3].
|
| ln Vivo |
In a human lung cancer xenograft mice model, yatein (20 mg/kg; intraperitoneal injection; five times per week; for 42 days) showed in vivo antitumor effects [3].
|
| Enzyme Assay |
Isolation of Microtubule Proteins[3]
The A549 and CL1-5 cells (1 × 106 cells) were seeded onto culture dishes (10 cm) overnight and treated with 5 μM Yatein. The cells were harvested through trypsinization and washed with PBS. After centrifugation, the supernatant was removed and the cell pellets were mixed with 200 μL of microtubule stabilizing buffer (1 mM MgCl2, 2 mM Tris-HCl, 2 mM EGTA, and 0.5% Triton-100 in ddH2O) and incubated at RT for 20 min. Subsequently, the mixture was centrifuged at 12,000× g for 10 min (4 °C) to obtain the supernatant (monomer tubulin fraction). The remaining cell pellets were washed using the microtubule stabilizing buffer and lysed in a radioimmunoprecipitation assay buffer containing 10% proteinase inhibitor and 10% phosphatase inhibitor at 4 °C for 30 min to obtain the polymer tubulin fraction. The monomer tubulin and polymer tubulin fractions were transferred into microtubes (1.5 mL) and stored at −20 °C until further analysis. |
| Cell Assay |
Cell cycle analysis [3]
Cell Types: A549 cells, CL1-5 cells Tested Concentrations: 1.25 μM, 2.5 μM, 5 μM Incubation Duration: 24 hrs (hours) Experimental Results: Both cell lines induced cell cycle arrest in the G2/M phase. Western Blot Analysis [3] Cell Types: A549 cells, CL1-5 cells Tested Concentrations: 5 μM Incubation Duration: 6 hrs (hours), 12 hrs (hours) Experimental Results: Up-regulates the expression of cyclin B1, but does not up-regulate the expression of Cdc2 and Cdc25c, and induces Cdc2 phosphorylation. |
| Animal Protocol |
Animal/Disease Models: Male NOD/SCID (severe combined immunodeficient) mouse (6-8 weeks), A549 cell xenografts [3]
Doses: 20 mg/kg Route of Administration: intraperitoneal (ip) injection, 5 times a week for 42 days Experimental Results: Significant tumor growth Slows down and modestly increases cyclin B1 expression and Cdc2 phosphorylation. In Vivo Antitumor Activity[3] The A549-luc cells were mixed with Matrigel (Sigma-Aldrich) at a 1:1 ratio. The cells were injected subcutaneously into the back of nonobese diabetic and severe combined immunodeficiency (NOD/SCID) mice (male, 6–8 weeks old) at a density of 3.5 × 106 cells/mouse. Tumors were allowed to grow for 10 days and were then treated with an intraperitoneal (i.p.) injection of either 0.5% DMSO in ddH2O to the mice in the vehicle control group (n = 5) or 20 mg/kg of yatein (dissolved in 0.5% DMSO in ddH2O) to the mice in the yatein group (n = 5). The tumor-bearing mice were sacrificed after 42 days. Tumor volume was measured five times/week and calculated using the following formula: Length × width × thickness × 0.5 (mm3). An IVIS (Caliper lifescience IVIS Spectrum CT) was used to analyze the luminescence of tumor tissue. |
| References |
|
| Additional Infomation |
Dihydroanhydropodorhizol is a member of the class of butan-4-olides carrying 3,4,5-trimethoxybenzyl and (1,3-benzodioxol-5-yl)methyl substituents at positions 3 and 4 respectively. It has a role as a plant metabolite. It is a lignan, a butan-4-olide, a member of methoxybenzenes and a member of benzodioxoles.
Yatein has been reported in Eleutherococcus divaricatus, Illigera luzonensis, and other organisms with data available. |
| Molecular Formula |
C22H24O7
|
|---|---|
| Molecular Weight |
400.427
|
| Exact Mass |
400.152
|
| Elemental Analysis |
C, 65.99; H, 6.04; O, 27.97
|
| CAS # |
40456-50-6
|
| PubChem CID |
442835
|
| Appearance |
Colorless to light yellow ointment
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
564.9±45.0 °C at 760 mmHg
|
| Flash Point |
246.2±28.8 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.577
|
| Source |
C. formosana leaves ; Fitzroya cupressoides (Molina) I. M. Johnst.; Austrocedrus chilensis (D. Don) Pic.Serm. & Bizzarri; Chamaecyparis obtusa; Chilean Cupressaceae
|
| LogP |
3.06
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
29
|
| Complexity |
541
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
COC1=C(C(=CC(=C1)C[C@@H]2[C@@H](CC3=CC4=C(C=C3)OCO4)COC2=O)OC)OC
|
| InChi Key |
GMLDZDDTZKXJLU-JKSUJKDBSA-N
|
| InChi Code |
InChI=1S/C22H24O7/c1-24-19-9-14(10-20(25-2)21(19)26-3)7-16-15(11-27-22(16)23)6-13-4-5-17-18(8-13)29-12-28-17/h4-5,8-10,15-16H,6-7,11-12H2,1-3H3/t15-,16+/m0/s1
|
| Chemical Name |
(3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-one
|
| Synonyms |
Dihydroanhydropodorhizol; (-)-yatein; (-)-deoxypodorhizone; Deoxypodorhizone; CHEBI:4553; CHEMBL471067; Yatein
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4973 mL | 12.4866 mL | 24.9732 mL | |
| 5 mM | 0.4995 mL | 2.4973 mL | 4.9946 mL | |
| 10 mM | 0.2497 mL | 1.2487 mL | 2.4973 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA